Our Pipeline

A dose-ranging Phase 2 trial that evaluated EDP1815 for the treatment of mild to moderate psoriasis. The trial evaluated three doses of EDP1815 versus placebo in approximately 225 individuals, over a 16-week treatment period. Potential registration trials in 2023.

Click here for information on our positive Phase 2 data in psoriasis.

A 16 week, double-blind, placebo-controlled trial. Approximately 405 participants will be randomized to receive either EDP1815 or placebo (295 to EDP1815: 110 to placebo) and treated for 16 weeks. Participants in Cohorts 1, 2, & 3 will be randomized in a 3:1 ratio (225 to EDP1815: 75 to placebo). Participants in Cohort 4 will be randomized in a 2:1 ratio (70 to EDP1815: 35 to placebo).

• Cohort 1: Dose of 1.6 x 10¹¹ total cells of EDP1815 or matching placebo administered as two capsules once daily.
• Cohort 2: Dose of 6.4 x 10¹¹ total cells of EDP1815 or matching placebo administered as two capsules once daily.
• Cohort 3: Dose of 3.2 x 10¹¹ cells of EDP1815 or matching placebo administered as one capsule twice daily.
• Cohort 4: Dose of 8.0 x 10¹¹ total cells of EDP1815 or placebo as one capsule, once daily.

Data from cohorts 1-3 expected in 1Q 2023. Data from cohort 4 expected in 2Q 2023.

Clinical trial initiation in 4Q 2022. Phase 2 psoriasis data anticipated in 2H 2023.

Chronic inflammation of the nervous system is believed to be a driver of neuro-inflammatory diseases (i.e. Multiple Sclerosis) and is also associated with neurodegenerative diseases (i.e. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, etc.) Evelo is studying the impact of single strains of microbes on neuro-inflammation in preclinical studies. The most notable effect is the clearance of inflammatory cells in the spinal cord by these microbes. SINTAX is an effective portal to central inflammatory pathways without the need to cross the blood-brain barrier. This is potentially transformational in the treatment of neuroinflammatory and neurodegenerative diseases which have an inflammatory drive to their pathology.

Metabolic syndrome, which affects more than 30% of adults in the US, increases one’s risk of developing cardiovascular disease and type 2 diabetes. Metabolic syndrome is often accompanied by low grade chronic inflammation, which is has been implicated in both its development and progression of associated pathologies. Evelo is investigating the therapeutic potential of single strains of microbes on multiple aspects of metabolic syndrome (i.e., excess body fat, insulin resistance, triglyceride levels) in preclinical models.